6 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
What's in the Cards for Sarepta (SRPT) This Earnings Season? http://www.zacks.com/stock/news/577120/whats-in-the-cards-for-sarepta-srpt-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-577120 Oct 22, 2019 - Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.
What's in the Cards for AstraZeneca (AZN) in Q3 Earnings? http://www.zacks.com/stock/news/575739/whats-in-the-cards-for-astrazeneca-azn-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-575739 Oct 21, 2019 - AstraZeneca's (AZN) third-quarter result is expected to reflect the impact of new drug sales.
Why the Earnings Surprise Streak Could Continue for Incyte (INCY) http://www.zacks.com/stock/news/571171/why-the-earnings-surprise-streak-could-continue-for-incyte-incy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-571171 Oct 18, 2019 - Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD http://www.zacks.com/stock/news/569743/novartis-jakavi-meets-primary-goal-in-phase-iii-for-gvhd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-569743 Oct 17, 2019 - Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
Editas Inks Deal for Gene Editing Neurological Disease Drugs http://www.zacks.com/stock/news/567847/editas-inks-deal-for-gene-editing-neurological-disease-drugs?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-567847 Oct 16, 2019 - Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
Novavax Begins Phase III Study on Influenza Vaccine Candidate http://www.zacks.com/stock/news/567846/novavax-begins-phase-iii-study-on-influenza-vaccine-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-567846 Oct 16, 2019 - Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.

Pages: 1

Page 1